1. At a Glance
Accretion Nutraveda is currently a financial paradox wrapped in an Ayurvedic label. On one hand, you have a company that has effectively doubled its top line in a single year, moving from ₹16.00 crore in March 2025 to a staggering ₹33.60 crore in March 2026. This 110% growth is the kind of number that sends retail investors into a frenzy, especially when paired with a Profit After Tax (PAT) that jumped 94% to hit ₹5.07 crore. However, behind this high-octane growth lies a balance sheet that is expanding faster than the company can manage.
The most glaring red flag is the Cash Flow from Operations (CFO), which has plummeted to a terrifying negative ₹23.92 crore. To put that in perspective, while the company is reporting profits on paper, it is burning cash at an industrial rate to fuel its working capital. Working capital days have exploded from 111 days to 352 days. Essentially, the company’s money is trapped in inventory and “other current assets” rather than sitting in the bank.
Investors are currently paying a P/E of 41.3, which is a significant premium compared to the industry median of 31.1. The market is clearly pricing in the aggressive expansion plans—specifically the ₹12 crore earmarked for a new manufacturing facility—but the massive jump in Other Current Assets to ₹10.09 crore (from zero) and Short-Term Loans and Advances to ₹7.75 crore suggests a complexity in the books that requires a detective’s lens. Is this a genuine scale-up or an over-leveraged dash for growth?
2. Introduction
Accretion Nutraveda Limited is a relatively new entrant in the healthcare space, having been incorporated only in 2021. In a span of just five years, it has transitioned from a private entity to a listed player on the BSE SME platform as of February 2026.
The company operates as a Contract Development and Manufacturing Organisation (CDMO). This means they aren’t just selling their own brand; they are the “kitchen” for other domestic clients and exporters who need Ayurvedic and Nutraceutical formulations.
Operating out of a leased facility in Ahmedabad, the company has managed to scale its product portfolio to over 72 formulations. This includes everything from liver detox capsules to joint pain oils.
However, the recent listing and the subsequent infusion of ₹24.76 crore from the IPO have fundamentally altered the company’s capital structure. The equity capital has jumped from a tiny ₹0.49 crore to ₹7.24 crore.
The management is now sitting on a pile of cash and a mandate to automate existing units and set up new ones. While the growth trajectory is undeniable, the sudden resignation of two independent directors on the very day the annual results were approved (May 8, 2026) adds a layer of “management churn” drama that investors cannot ignore.
3. Business Model – WTF Do They Even Do?
Accretion Nutraveda is essentially a specialized factory-for-hire. If you want to launch a “Natural Liver Detox” capsule but don’t want to build a factory, you go to them.
They operate across six major segments:
- External Preparations: Balms, creams, and inhalers (The biggest revenue driver at 38.2%).
- Tablets & Capsules: Core nutraceuticals like multivitamins and organ support.
- Oral Liquids & Powders: Syrups and protein blends.
The business model is heavily concentrated. Gujarat accounts for 96.28% of their revenue. They are a local hero trying to pretend they are a
